Blog · Consumer · Published 2026-08-09
Medicare's ~$50 Obesity-Med Tier: What It Means If You've Been Paying Cash for Compounded GLP-1s
Released: · Last reviewed:
Since July 1, 2026, the CMS Medicare GLP-1 Bridge lets eligible Part D enrollees pay a $50 copay for covered FDA-approved products, outside the Part D benefit, through December 31, 2027. Medicare.gov says the Bridge covers Foundayo, Wegovy and the Zepbound KwikPen, for people with a BMI of 35 or more, or lower thresholds with listed conditions. For a Medicare-eligible reader paying cash in the compounded market — $49 to $449 a month all-in in our October 15, 2026 index, where the only figures under $50 are $49 semaglutide sale or "starting at" prices — the arithmetic is blunt: a $50 covered brand product is at or below almost every cash figure here. Eligibility is criteria-bound, but the order of operations has permanently changed: check the coverage door before shopping the cash market, not after.
How to actually run the check
Three steps, all free. First, check the Bridge criteria on Medicare.gov — a BMI of 35 or more, or lower thresholds with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; Medicare.gov says their Part D plan might cover a GLP-1, so read that plan's formulary and criteria. Second, have your prescriber file on the strongest applicable indication with documentation attached; initial denials are common and appealable. Third, price the year — the $50 copay applies to eligible enrollees on covered products from July 1, 2026 to December 31, 2027, and Part D plan coverage outside the Bridge varies by plan. If the door opens, the compounded market's price case ends for you; if it stays shut, the cash market remains, and this site's normalized figures are how to shop it.
What this does not change
Compounded semaglutide and tirzepatide are not FDA approved and are not covered by the Bridge — it applies to approved products only, which is precisely why the compounded-vs-brand comparison keeps the categories separate. Nor does coverage eligibility make cash figures irrelevant for everyone: non-qualifying patients, excluded plans, and coverage gaps keep a real cash market, where the current price tables for compounded tirzepatide and compounded semaglutide (read October 15, 2026) and the pricing-literacy guide apply unchanged. The update here is sequence, not substance: coverage first, cash second, and never the reverse by default.
Frequently asked questions
Does Medicare cover compounded GLP-1s?
No — the Medicare GLP-1 Bridge applies to FDA-approved products (Foundayo, Wegovy and the Zepbound KwikPen, per Medicare.gov) for eligible Part D enrollees. Compounded products are not FDA approved and sit outside it.
Who qualifies for the ~$50 Medicare tier?
Per Medicare.gov, Part D enrollees with a BMI of 35 or more, or lower thresholds with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1, so check its formulary.
Should I stop paying cash for compounded GLP-1s if I'm on Medicare?
Run the coverage check first: a $50 covered copay is at or below almost every cash figure in our October 15, 2026 index (the only lower figures are $49 semaglutide sale or "starting at" prices). If your plan's criteria exclude you, the cash market — compounded and brand self-pay — remains, priced on the site's normalized figures.
Primary sources
Coverage details derive from CMS and Medicare.gov pages on the Medicare GLP-1 Bridge; Part D plan coverage outside the Bridge varies by plan. Brand-product context per manufacturer program pages and FDA announcements.